We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
Cap. Flow
-$8.88M
Cap. Flow %
-0.86%
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$21.3M
2
ANGO icon
AngioDynamics
ANGO
+$13.9M
3
XENT
Intersect ENT, Inc
XENT
+$11.1M
4
MDCO
Medicines Co
MDCO
+$9.01M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.81M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$18.7M
2
XNPT
XENOPORT, INC.
XNPT
+$7.18M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$6.39M
4
ELOS
Syneron Medical Ltd
ELOS
+$6.36M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$5.34M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
26
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.2M 1.09%
803,332
+273,050
+51% +$4.02M
AMRN
27
Amarin Corp
AMRN
$285M
$10.1M 0.98%
233,761
– –
DSCI
28
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$10.1M 0.98%
2,562,104
– –
XENT
29
DELISTED
Intersect ENT, Inc
XENT
$9.19M 0.89%
+710,600
New +$11.1M
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.05M 0.88%
+177,400
New +$8.81M
MDCO
31
DELISTED
Medicines Co
MDCO
$8.6M 0.84%
+255,600
New +$9.01M
HZNP
32
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.23M 0.8%
500,000
-1,000,000
-67% -$16.2M
RDHL
33
Redhill Biopharma
RDHL
$4.26M
$8.01M 0.78%
737
-81
-10% -$937K
DVAX
34
DELISTED
Dynavax Technologies
DVAX
$7.99M 0.78%
547,810
– –
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$7.1M 0.69%
882,312
– –
GHDX
36
DELISTED
Genomic Health, Inc.
GHDX
$7M 0.68%
+270,400
New +$7.18M
ARCT icon
37
Arcturus Therapeutics
ARCT
$170M
$6.99M 0.68%
222,444
– –
CORI
38
DELISTED
Corium International, Inc.
CORI
$6.66M 0.65%
1,919,721
+117,629
+7% +$479K
ADMA icon
39
ADMA Biologics
ADMA
$2.03B
$6.62M 0.64%
1,113,293
+149,100
+15% +$1.04M
SBBP
40
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.59M 0.64%
1,656,706
+1
+0% +$5
ASRT
41
DELISTED
Assertio
ASRT
$6.37M 0.62%
+5,411
New +$5.92M
QLTI
42
DELISTED
QLT Inc
QLTI
$6.31M 0.61%
4,445,527
– –
AEGR
43
DELISTED
Aegerion Pharmaceuticals
AEGR
$5.97M 0.58%
4,010,291
– –
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
$5.82M 0.57%
8,200,000
– –
EGLT
45
DELISTED
Egalet Corporation
EGLT
$5.63M 0.55%
1,134,750
– –
TENX icon
46
Tenax Therapeutics
TENX
$416M
$5.04M 0.49%
62
– –
VXRT
47
DELISTED
Vaxart
VXRT
$4.88M 0.47%
316,974
– –
ACGN
48
DELISTED
Aceragen Inc
ACGN
$4.74M 0.46%
22,778
– –
NVET
49
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$4.64M 0.45%
1,000,000
– –
MDWD icon
50
MediWound
MDWD
$188M
$4.19M 0.41%
75,855
– –
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital's Q2 2016 filing shows 13 new, 14 increased, 14 reduced and 14 closed positions. Its largest new stake was Endo International plc: 1,028,802 shares worth $16M. The largest sale was NEVRO CORP., an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 71% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2016 buy was Endo International plc: 1,028,802 shares worth $16M.
  • Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
  • Broadfin Capital's biggest Q2 2016 reduction was NEVRO CORP., cutting an estimated $18.7M.
  • Broadfin Capital fully exited XENOPORT, INC. in Q2 2016, selling an estimated $7.18M.
  • Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
  • Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.